Highlights from

SPIN 2019

Skin Inflammation & Psoriasis International Network

Paris 25-27 April 2019

Sustained and complete responses from the phase 3 AMAGINE-2 and -3 studies

A post-hoc analysis of the phase 3 AMAGINE-2 and AMAGINE-3 trials including 3,712 people with moderate-to-severe psoriasis shows that 90% of patients treated with brodalumab who achieved Psoriasis Area and Severity Index (PASI) score of 100 also experienced a sustained PASI-100 score [1]. In the same analysis, only 77% of patients treated with ustekinumab who achieved PASI 100 also experienced sustained PASI 100. Study authors measured sustained PASI-100 as the time to inadequate response, based on a static physician's global assessment (sPGA) of ≥3 or persistent values of 2 over at least a 4-week period at or after week 16. Since the sub-populations of patients treated with brodalumab and ustekinumab in these studies had different baseline characteristics, the study authors did not apply statistical comparisons.

"Newer treatments for moderate-to-severe psoriasis have made it possible for patients to completely clear their skin, but the disease fluctuates over time; so we wanted to explore how fast and for how long patients can count on having complete skin clearance," said Professor Lluís Puig (Hospital de la Santa Creu i Sant Pau, Spain). "These results show that brodalumab can offer more patients a longer, more sustained period of complete skin clearance than ustekinumab. That difference can have a big impact on patients' quality of life."

  1. Warren et al. Complete clearance and cumulative benefit by psoriasis area and severity index (PASI) for brodalumab and ustekinumab in AMAGINE-2 and -3. Abstract P069, SPIN 2019, 25-27 April, Paris, France.

The content and interpretation of these conference highlights are the views and comments of the speakers/authors.